Correction to Lancet Gastroenterol Hepatol 2023; 8: 976–89

Abstract

Vermeire S, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. Lancet Gastroenterol Hepatol 2023; 8: 976–89—In this Article, the declaration of interest statement for PDRH should read: “PDRH has received grants from AbbVie, the Crohn's & Colitis Foundation, the National Institutes of Health, and Takeda; and has served as a consultant for AbbVie, Eli Lilly, the Gastrointestinal Health Foundation, Imedex, Pfizer, Takeda, and Vindico Medical Education.” This correction has been made to the online version as of Feb 12, 2025.